350 FIFTH AVENUE, NEW YORK, NY
Directors Elected at Daxor Corporation Annual Meeting; Voting Results Disclosed
Daxor Corporation Enters Definitive Securities Purchase Agreement for $8.14M
Other Events
Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Shareholder votes
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
FY 2011
Q3
Q2 amended
Q2
Q1
FY 2010
Prospectus filed pursuant to Rule 424(b)(4)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration of Securities
Certificate
SEC Form 25 - Delisting Notification
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Investment Company Act Rule 8f-2 Notice
NT NPORT-P
Semi-Annual Financial Report for Management Investment Companies
Amended Registration Statement for Closed-End Management Investment Companies